Choroby zapalne jelit jako problem zdrowia publicznego – przegląd piśmiennictwa

Paweł Moćko¹, Paweł Kawalec¹, Andrzej Pilc²

Summary
The number of patients with inflammatory bowel disease, both in Poland and in the world is growing rapidly in recent years, and becoming an increasing problem of medical, social and economic. The group of inflammatory bowel diseases include Crohn’s disease (CD) and ulcerative colitis (UC). We conduct a review of the available literature by searching a medical databases. We included a trials that compared efficacy and safety of drugs funded in Poland in the treatment of CD and UC, i.e. infliximab and adalimumab, and other modern biological agents available in the world (certolizumab pegol, vedolizumab, etrolizumab, ustekinumab, adalimumab). Results of the review showed higher efficiency of analyzed drugs compared with placebo on the patient clinically relevant endpoints, i.e. responses to treatment (induction phase and maintain phase) and clinical remission (induction phase and maintain phase). A choice of a treatment method should be preceded by an analysis of the specific case in order to give optimal results. What’s more in this paper also provides information about the available drug treatment programs of inflammatory bowel disease in Poland and the costs associated with the refund of these drugs.

To jest tylko fragment artykułu. Aby przeczytać całość, przejdź do Czytelni medycznej.